ProMIS Neurosciences (PMN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $8.15, -6.32% vs the prior close of $8.70.
- Volume 20.42K shares, 0.6x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PMN slides 6.3% to $8.15, a 6-month low. Closed at $8.15, -6.32% vs the prior close of $8.70. Day range $7.93–$9.42, opened at $8.45.
PMN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — PMN slides 6.3% to $8.15, a 6-month low
- Closed at $8.15, -6.32% vs the prior close of $8.70. Day range $7.93–$9.42, opened at $8.45.
- Volume was 20.42K shares, 0.6x its 50-day average of 35.00K — lighter than usual.
- Price is -34.8% vs its 50-day average ($12.49) and -36.6% vs its 200-day average ($12.86).
- 52-week range $6.27–$27.40; today's close sits at 9% of that range, 70.3% below the 52-week high.
Oct 15, 2026 — PMN jumps 4.9% to $8.70
- Closed at $8.70, +4.95% vs the prior close of $8.29. Day range $8.00–$8.87, opened at $8.29.
- Volume was 33.50K shares, 1.0x its 50-day average of 35.26K.
- Price is -30.9% vs its 50-day average ($12.59) and -32.3% vs its 200-day average ($12.85).
- 52-week range $6.27–$27.40; today's close sits at 12% of that range, 68.2% below the 52-week high.
Oct 14, 2026 — PMN slides 4.3% to $8.29, a 6-month low, 3 down days in a row
- Closed at $8.29, -4.27% vs the prior close of $8.66. Day range $8.16–$8.81, opened at $8.41.
- Volume was 23.40K shares, 0.7x its 50-day average of 35.17K.
- Price is -34.7% vs its 50-day average ($12.69) and -35.5% vs its 200-day average ($12.84).
- 52-week range $6.27–$27.40; today's close sits at 10% of that range, 69.7% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — PMN slides 8.4% to $8.66, a 6-month low
- Closed at $8.66, -8.36% vs the prior close of $9.45. Day range $8.51–$9.47, opened at $9.38.
- Volume was 27.10K shares, 0.8x its 50-day average of 34.98K.
- Price is -32.3% vs its 50-day average ($12.80) and -32.6% vs its 200-day average ($12.84).
- 52-week range $6.27–$27.40; today's close sits at 11% of that range, 68.4% below the 52-week high.
Oct 12, 2026 — PMN dips 1.7% to $9.45
- Closed at $9.45, -1.66% vs the prior close of $9.61. Day range $9.20–$9.78, opened at $9.61.
- Volume was 23.70K shares, 0.7x its 50-day average of 35.19K.
- Price is -26.8% vs its 50-day average ($12.91) and -26.4% vs its 200-day average ($12.84).
- 52-week range $6.27–$27.40; today's close sits at 15% of that range, 65.5% below the 52-week high.
Oct 9, 2026 — PMN jumps 5.0% to $9.61
- Closed at $9.61, +5.03% vs the prior close of $9.15. Day range $9.06–$10.15, opened at $9.06.
- Volume was 18.80K shares, 0.5x its 50-day average of 35.72K — lighter than usual.
- Price is -26.0% vs its 50-day average ($12.99) and -25.1% vs its 200-day average ($12.83).
- 52-week range $6.27–$27.40; today's close sits at 16% of that range, 64.9% below the 52-week high.
Oct 8, 2026 — PMN rises 0.3% to $9.15
- Closed at $9.15, +0.33% vs the prior close of $9.12. Day range $8.78–$9.37, opened at $9.02.
- Volume was 35.30K shares, 0.9x its 50-day average of 40.28K.
- Price is -30.1% vs its 50-day average ($13.10) and -28.6% vs its 200-day average ($12.82).
- 52-week range $6.27–$27.40; today's close sits at 14% of that range, 66.6% below the 52-week high.
Oct 7, 2026 — PMN dips 1.0% to $9.12, a 6-month low, 3 down days in a row
- Closed at $9.12, -0.98% vs the prior close of $9.21. Day range $9.01–$9.52, opened at $9.17.
- Volume was 25.10K shares, 0.3x its 50-day average of 75.24K — lighter than usual.
- Price is -30.9% vs its 50-day average ($13.20) and -28.9% vs its 200-day average ($12.82).
- 52-week range $6.27–$27.40; today's close sits at 13% of that range, 66.7% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — PMN dips 1.7% to $9.21, a 3-month low
- Closed at $9.21, -1.71% vs the prior close of $9.37. Day range $8.78–$9.52, opened at $9.46.
- Volume was 26.40K shares, 0.3x its 50-day average of 76.68K — lighter than usual.
- Price is -30.8% vs its 50-day average ($13.30) and -28.1% vs its 200-day average ($12.82).
- 52-week range $6.27–$27.40; today's close sits at 14% of that range, 66.4% below the 52-week high.
Oct 5, 2026 — PMN dips 0.3% to $9.37, a 3-month low
- Closed at $9.37, -0.32% vs the prior close of $9.40. Day range $9.07–$9.77, opened at $9.50.
- Volume was 38.20K shares, 0.5x its 50-day average of 77.76K — lighter than usual.
- Price is -29.8% vs its 50-day average ($13.35) and -26.9% vs its 200-day average ($12.82).
- 52-week range $6.27–$27.40; today's close sits at 15% of that range, 65.8% below the 52-week high.
Oct 2, 2026 — PMN ends flat (+0.2%) to $9.40
- Closed at $9.40, +0.21% vs the prior close of $9.38. Day range $9.16–$10.38, opened at $9.44.
- Volume was 27.30K shares, 0.3x its 50-day average of 79.36K — lighter than usual.
- Price is -29.9% vs its 50-day average ($13.41) and -26.7% vs its 200-day average ($12.82).
- 52-week range $6.27–$27.40; today's close sits at 15% of that range, 65.7% below the 52-week high.
PMN latest news & SEC filings
Every SEC filing by or about PMN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 6, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$11.73M (prior year -$10.12M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.28 (prior year -$7.26) (loss narrowed vs Jun 30, 2025)
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kaplan Johanne bought 2,280 shares at $13.30 (≈$30.32K) on Aug 5, 2026
- Kaplan Johanne bought 2,280 shares at $13.30 (≈$30.32K) on Aug 5, 2026
- Kaplan Johanne bought 2,280 shares at $13.30 (≈$30.32K) on Aug 5, 2026
- Kaplan Johanne bought 2,280 shares at $13.30 (≈$30.32K) on Aug 5, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade PMN
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 25, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.81% (largest 13.5%). That is a volatile stock.
- Liquidity: about 34.65K shares (≈$282.36K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $8.15 vs a range of $6.27–$27.40 (9% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:25 on Nov 28, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Johanne Kaplan bought 2,280 shares on Aug 5, 2026.
- Latest filings: 8-K Aug 13, 2026; 10-Q Aug 13, 2026; 8-K Jul 28, 2026.
- Share count: 8.97M shares outstanding (Aug 13, 2026), -82.7% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
PMN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 8.45 | 9.42 | 7.93 | 8.15 | 20.42K |
| Oct 15, 2026 | 8.29 | 8.87 | 8.00 | 8.70 | 33.50K |
| Oct 14, 2026 | 8.41 | 8.81 | 8.16 | 8.29 | 23.40K |
| Oct 13, 2026 | 9.38 | 9.47 | 8.51 | 8.66 | 27.10K |
| Oct 12, 2026 | 9.61 | 9.78 | 9.20 | 9.45 | 23.70K |
| Oct 9, 2026 | 9.06 | 10.15 | 9.06 | 9.61 | 18.80K |
| Oct 8, 2026 | 9.02 | 9.37 | 8.78 | 9.15 | 35.30K |
| Oct 7, 2026 | 9.17 | 9.52 | 9.01 | 9.12 | 25.10K |
| Oct 6, 2026 | 9.46 | 9.52 | 8.78 | 9.21 | 26.40K |
| Oct 5, 2026 | 9.50 | 9.77 | 9.07 | 9.37 | 38.20K |
| Oct 2, 2026 | 9.44 | 10.38 | 9.16 | 9.40 | 27.30K |
| Oct 1, 2026 | 10.98 | 10.98 | 9.21 | 9.38 | 102.10K |
| Sep 30, 2026 | 10.68 | 11.32 | 10.42 | 10.85 | 12.70K |
| Sep 29, 2026 | 10.56 | 11.10 | 10.53 | 10.64 | 16.90K |
| Sep 28, 2026 | 11.15 | 11.57 | 10.51 | 10.65 | 25.10K |
| Sep 25, 2026 | 12.06 | 12.06 | 11.15 | 11.27 | 20.10K |
| Sep 24, 2026 | 12.83 | 13.06 | 11.29 | 11.57 | 52.70K |
| Sep 23, 2026 | 13.45 | 13.78 | 12.94 | 12.94 | 43.70K |
| Sep 22, 2026 | 13.80 | 14.22 | 13.45 | 13.58 | 94.20K |
| Sep 21, 2026 | 13.54 | 14.22 | 13.13 | 13.63 | 26.20K |
About ProMIS Neurosciences
ProMIS Neurosciences (PMN) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in TORONTO, Ontario, Canada. State of incorporation: Canada (Federal Level). Fiscal year ends December 31. SEC CIK 1374339.
PMN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Slanix Paul Alex | Director | May 22, 2026 |
| Neil Cashman | Chief Scientific Officer | May 22, 2026 |
| Patrick D. Kirwin | Director | Apr 23, 2026 |
| Josh Mandel-Brehm | Director | May 22, 2026 |
| Madge K. Shafmaster | Director | May 22, 2026 |
| William W Wyman | Director | May 22, 2026 |
| Neil K Warma | Chief Executive Officer | May 22, 2026 |
| Eugene Williams | Director | May 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Neil Cashman | Chief Scientific Officer | May 22, 2026 |
| Johanne Kaplan | Chief Development Officer | Aug 7, 2026 |
| Max A. Milbury | Principal Accounting Officer | May 22, 2026 |
| Neil K Warma | Chief Executive Officer | May 22, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 5, 2026 | Johanne Kaplan | Buy | 2,280 | $13.30 |
| Aug 5, 2026 | Johanne Kaplan | Buy | 2,280 | $13.30 |
| Aug 5, 2026 | Johanne Kaplan | Buy | 2,280 | $13.30 |
| Aug 5, 2026 | Johanne Kaplan | Buy | 2,280 | $13.30 |
| Apr 22, 2026 | Patrick D. Kirwin | Buy | 4,000 | $11.33 |
| Apr 22, 2026 | Patrick D. Kirwin | Buy | 4,000 | $11.33 |
| Apr 22, 2026 | Patrick D. Kirwin | Buy | 4,000 | $11.33 |
| Apr 22, 2026 | Patrick D. Kirwin | Buy | 4,000 | $11.33 |
| Mar 5, 2026 | Eugene Williams | Buy | 2,000 | $24.40 |
| Mar 5, 2026 | Eugene Williams | Buy | 2,000 | $24.40 |
| Mar 5, 2026 | Eugene Williams | Buy | 2,000 | $24.40 |
| Mar 5, 2026 | Eugene Williams | Buy | 2,000 | $24.40 |
| Mar 4, 2026 | Eugene Williams | Buy | 2,000 | $24.00 |
| Mar 4, 2026 | Eugene Williams | Buy | 2,000 | $24.00 |
| Mar 4, 2026 | Eugene Williams | Buy | 2,000 | $24.00 |
PMN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-39.72M | -22.61 | $-28.12M |
| Dec 31, 2024 | — | $2.78M | 2.63 | $-27.18M |
| Dec 31, 2023 | — | $-13.21M | -1.07 | $-10.84M |
| Dec 31, 2022 | — | $-18.06M | -2.41 | $-17.03M |
| Dec 31, 2021 | — | $-9.79M | -1.69 | $-9.31M |
Latest balance sheet: total assets $56.69M, total liabilities $7.29M, cash $53.43M (as of Jun 30, 2026).
PMN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $14.79 |
| May 12, 2026 | 8-K Item 2.02 (results) | $10.49 |
| Mar 25, 2026 | 8-K Item 2.02 (results) | $15.85 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $10.25 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $17.50 |
| May 12, 2025 | 8-K Item 2.02 (results) | $12.50 |
| Mar 31, 2025 | 8-K Item 2.02 (results) | $17.50 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $24.75 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Apr 1, 2024 | 8-K Item 2.02 (results) | — |
| Nov 14, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on PMN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.